clobetasol has been researched along with Erythema-Multiforme* in 5 studies
1 trial(s) available for clobetasol and Erythema-Multiforme
Article | Year |
---|---|
Double-blind clinical trial of 0.05% clobetasol propionate (corrected from proprionate) ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases.
Because of their chronic nature treatment of oral vesiculoerosive diseases remains a challenge to the oral medicine specialist. Even though oral vesiculoerosive diseases respond well to systemic steroids, adverse side effects sometimes limit their use. Potent topical steroids are becoming increasingly useful to treat these chronic conditions with good control. The purpose of this double-blind clinical trial was to compare clobetasol propionate and fluocinonide ointment in orabase as treatments for controlling oral vesiculoerosive diseases. Sixty patients were asked to participate (43 women and 17 men). Data are reported for 55 patients. Each patient was seen at baseline and at days 7, 14, 21, and 28. Variables evaluated were pain, erythema, atrophy, and size of lesion. Overall, both medications had a beneficial effect in the control of symptoms and signs of oral vesiculoerosive diseases with minimal side effects. Clobetasol propionate was better than fluocinonide as measured by more rapid control of pain (within 7 days). Candidiasis was observed in 13 patients at the end of treatment (most of them carriers of Candida). Therefore normal carriers should be identified and treatment with antifungal therapy instituted before the patient begins using topical steroids. Topics: Aged; Carboxymethylcellulose Sodium; Clobetasol; Double-Blind Method; Erythema Multiforme; Female; Fluocinonide; Humans; Lichen Planus, Oral; Linear Models; Male; Middle Aged; Mouth Diseases; Pemphigoid, Benign Mucous Membrane; Pemphigus | 1994 |
4 other study(ies) available for clobetasol and Erythema-Multiforme
Article | Year |
---|---|
A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.
Topics: Administration, Topical; BNT162 Vaccine; Clobetasol; COVID-19; COVID-19 Vaccines; Erythema Multiforme; Female; Glucocorticoids; Humans; Middle Aged; Preexisting Condition Coverage; SARS-CoV-2; Symptom Flare Up; Treatment Outcome | 2021 |
Erythema multiforme like reaction to santos rosewood (
Erythema multiforme is a skin disorder characterised by target epithelial eruption, which is mainly caused by infection or drugs. In this case, we report an erythema multiforme like reaction caused by contact dermatitis against wood, especially santos rosewood. During the hospitalisation, we performed a patch test with lumber used in the patient's workplace, and recognised a positive response to multiple woods and a simultaneous recurring eruption (flare up) outside of the test site. The findings from this case of contact dermatitis caused by frequently used industrial wood type is important for the management of occupational environments. A review of the literature on erythema multiforme like reaction due to contact dermatitis, including past case reports, has also been provided. Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatitis, Allergic Contact; Erythema Multiforme; Fabaceae; Humans; Male; Occupational Diseases; Patch Tests; Taxaceae; Wood | 2019 |
Rowell's syndrome induced by terbinafine.
Terbinafine, a systemic antifungal commonly prescribed for onychomycosis (fungal infection involving the nails) has been reported to cause various cutaneous adverse effects. We describe an overlap syndrome between cutaneous lupus and erythaema multiforme induced by this medication with a review of other reported cases. Topics: Aged, 80 and over; Anti-Inflammatory Agents; Antifungal Agents; Clobetasol; Dermatologic Agents; Diagnosis, Differential; Erythema Multiforme; Female; Humans; Lupus Erythematosus, Cutaneous; Naphthalenes; Ointments; Onychomycosis; Syndrome; Terbinafine; Treatment Outcome | 2015 |
Severe reaction to diphosphonate: implications for treatment of Paget's disease.
Topics: Clobetasol; Drug Hypersensitivity; Erythema Multiforme; Female; Humans; Middle Aged; Osteitis Deformans; Technetium Tc 99m Medronate; Vasculitis | 1988 |